InspireMD(NSPR)

Search documents
InspireMD(NSPR) - 2024 Q1 - Quarterly Report
2024-05-13 20:15
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2123838 (State or other jurisdiction ...
InspireMD(NSPR) - 2023 Q4 - Earnings Call Transcript
2024-03-06 16:30
InspireMD Inc. (NASDAQ:NSPR) Q4 2023 Earnings Conference Call March 6, 2024 8:30 AM ET Company Participants Charles Padala - Investor Relations, LifeSci Advisors Marvin Slosman - President and Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Adam Maeder - Piper Sandler Ben Haynor - Alliance Global Partners Operator Greetings. Welcome to InspireMD Fourth Quarter and Full Year 2023 Earnings Call. [Operator Instructions] Please note, this conference is being recorded. ...
InspireMD(NSPR) - 2023 Q4 - Annual Results
2024-03-06 12:07
Exhibit 99.1 InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update - Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company's ongoing U.S. Investigational Device Exemption (IDE) clinical trial, C- GUARDIANS, designed to support U.S. approval of CGuard Prime - - Named Patrick Geraghty, M.D. and Patrick Muck, M.D. as lead principal investigators for the Company's C- ...
InspireMD(NSPR) - 2023 Q4 - Annual Report
2024-03-05 21:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2123838 (State or other jurisdiction of incorporation or organization) 4 Menor ...
InspireMD(NSPR) - 2023 Q3 - Quarterly Report
2023-11-06 21:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2123838 (State or other jurisdict ...
InspireMD(NSPR) - 2023 Q3 - Earnings Call Transcript
2023-11-06 16:09
InspireMD Inc. (NASDAQ:NSPR) Q3 2023 Results Earnings Conference Call November 6, 2023 8:30 AM ET Company Participants Charles Padala - Investor Relations, LifeSci Advisors Marvin Slosman - President, CEO and Director Craig Shore - Chief Financial Officer Conference Call Participants Adam Maeder - Piper Sandler Benjamin Haynor - Alliance Global Partners Operator Good morning. And welcome to the InspireMD Third Quarter of 2023 Earnings Call. Currently, all participants are in a listen-only mode. A question-a ...
InspireMD(NSPR) - 2023 Q2 - Earnings Call Transcript
2023-08-08 15:18
InspireMD Inc. (NASDAQ:NSPR) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Glenn Garmont - IR Marvin Slosman - President, CEO and Director Amir Kohen - Interim CFO, Secretary and Treasurer Conference Call Participants Adam Maeder - Piper Sandler Benjamin Haynor - Alliance Global Partners Operator Good morning, and welcome to the InspireMD Second Quarter 2023 Earnings Call. Currently all participants are in a listen-only mode. [Operator Instructions] After today’s presentatio ...
InspireMD(NSPR) - 2023 Q2 - Quarterly Report
2023-08-07 21:25
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2123838 (State or other jurisdiction o ...
InspireMD(NSPR) - 2023 Q1 - Earnings Call Transcript
2023-05-16 15:24
Start Time: 08:30 January 1, 0000 8:53 AM ET InspireMD, Inc. (NASDAQ:NSPR) Q1 2023 Earnings Conference Call May 16, 2023, 08:30 AM ET Company Participants Marvin Slosman - CEO Craig Shore - CFO Glenn Garmont - IR, LifeSci Advisors Conference Call Participants Benjamin Haynor - Alliance Global Partners Operator Good day, and welcome to the InspireMD First Quarter 2023 Earnings Call. All participants will be in listen-only mode. [Operator Instructions]. After today's presentation, there will be an opportunity ...
InspireMD(NSPR) - 2023 Q1 - Quarterly Report
2023-05-15 20:06
FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireMD, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of registrant as specified in its charter) Delaware 26-2123838 (State or other jurisdiction ...